Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer
…, JA O'Donoghue, S Welt, J O'Neel… - Journal of Nuclear …, 2004 - Soc Nuclear Med
This trial was performed to determine the maximum tolerated whole-body radiation-absorbed
dose of fractionated 131 I-cG250. Methods: This was a phase 1 dose escalation trial. Dose …
dose of fractionated 131 I-cG250. Methods: This was a phase 1 dose escalation trial. Dose …
Tumor burden assessment with positron emission tomography with [18-F] 2-fluoro 2-deoxyglucose (FDG PET) modeled in metastatic renal cell cancer
…, V Ng, SM Larson, JA O'Donoghue, J O'Neel… - Clinical Positron …, 2000 - Elsevier
Objective: In patients with advanced cancer, total tumor burden affects the likelihood of tumor
response and has important implications for prognosis. The aim of this study was to select …
response and has important implications for prognosis. The aim of this study was to select …
[HTML][HTML] ANCA-associated vasculitis: an update
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) represents a
group of small vessel vasculitides characterized by granulomatous and neutrophilic tissue …
group of small vessel vasculitides characterized by granulomatous and neutrophilic tissue …
[HTML][HTML] Renal recovery for patients with ANCA-associated vasculitis and low eGFR in the ADVOCATE trial of avacopan
…, F Maurier, R Mesbah, O Moranne, A Neel… - Kidney international …, 2023 - Elsevier
Introduction In the 330-patient ADVOCATE trial of avacopan for the treatment of antineutrophil
cytoplasmic autoantibody (ANCA)-associated vasculitis, in which 81% of patients had …
cytoplasmic autoantibody (ANCA)-associated vasculitis, in which 81% of patients had …
The impact of treatment with Avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the …
…, F Maurier, R Mesbah, O Moranne, A Neel… - The Lancet …, 2023 - thelancet.com
Background Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is
characterised by inflammation and destruction of small to medium sized blood vessels. In the …
characterised by inflammation and destruction of small to medium sized blood vessels. In the …
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis: a randomized trial
K De Groot, L Harper, DRW Jayne… - Annals of internal …, 2009 - acpjournals.org
Background: Current therapies for antineutrophil cytoplasmic antibody (ANCA)–associated
vasculitis are limited by toxicity. Objective: To compare pulse cyclophosphamide with daily …
vasculitis are limited by toxicity. Objective: To compare pulse cyclophosphamide with daily …
[HTML][HTML] Imaging in drug development: will it deliver on the promise of personalised medicine?
A Dzik-Jurasz - The British Journal of Radiology, 2010 - birpublications.org
… I would like to thank Dr Haren Rupani, Dr Philip Murphy and Ms Jayne O'Neel for their … I
would like to thank Dr Haren Rupani, Dr Philip Murphy and Ms Jayne O'Neel for their critical …
would like to thank Dr Haren Rupani, Dr Philip Murphy and Ms Jayne O'Neel for their critical …
Stimuli‐responsive release of antimicrobials using hybrid inorganic nanoparticle‐associated drug‐delivery systems
Recently, the combination of metallic nanoparticles (NPs) of Au, Ag, Fe 2 O 3 , and Fe 3 O 4
with traditional soft matter drug‐delivery systems has emerged as a promising strategy to …
with traditional soft matter drug‐delivery systems has emerged as a promising strategy to …
Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines
…, L Smyth, RA Watts, LC Willcocks, DRW Jayne - …, 2020 - academic.oup.com
Background Anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV)
encompasses three disease phenotypes: granulomatosis with polyangiitis (GPA), microscopic …
encompasses three disease phenotypes: granulomatosis with polyangiitis (GPA), microscopic …
Long-term outcome in idiopathic granulomatous mastitis: a western multicentre study
A Néel, M Hello, A Cottereau… - … Journal of Medicine, 2013 - academic.oup.com
Aim: To investigate the presentation, disease course and long-term outcome of a western
cohort of idiopathic granulomatous mastitis (IGM) and to analyse the impact of different …
cohort of idiopathic granulomatous mastitis (IGM) and to analyse the impact of different …